Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis
Frontiers in Pharmacology · 13.12.2023 · 14
DOI: 10.3389/fphar.2023.1281050 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.12.2023. Verfasst von Pajaree Mongkhon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacoepidemiology, Social and Administrative Pharmacy (PSAP) Research Unit, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thail…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Metformin has recently been demonstrated to have an anti-melanogenic activity. Nevertheless, clinical evidence of the effectiveness of metformin in melasma is lacking. The objective of this study was to assess the efficacy and safety of metformin in the treatment of melasma.
Methods
MEDLINE, Embase, PubMed, Cochrane Library (CENTRAL), Scopus, CINAHL, and grey literature databases were searched to 4 October 2022 and updated on 26 February 2023. Randomized controlled trials (RCTs), quasi-RCTs, observational studies, case series, and case reports investigating the efficacy and safety of metformin for melasma were included. The Melasma Area Severity Index (MASI) scores that changed from baseline were pooled using fixed-effects model and expressed as standardized mean differences (SMDs) and 95% confidence intervals (CIs).
Results
Three RCTs including 140 patients with melasma were included. The results demonstrated that after 8 weeks, 15% topical metformin significantly reduced the Melasma Area Severity Index (MASI) score compared to placebo (1 trial; n = 60; MD, −0.56; 95% CI, −1.07 to −0.04; p = 0.034). Furthermore, when compared to triple combination cream (TCC), 30% topical metformin demonstrated similar efficacy in reducing the MASI score after 8 weeks (2 trials; n = 80; MD, 0.19, 95% CI, −0.25 to 0.63; p = 0.390). Patients using 30% topical metformin had fewer adverse events compared to TCC users, although no statistical difference was found.
Conclusion
Topical metformin was as effective as triple combination cream (TCC) in decreasing changes in the MASI score in patients with melasma, with minimum adverse events. Further studies with larger sample sizes, longer follow-up times, and well-designed trials are required. Systematic Review Registration: Identifier PROSPERO (CRD42022351966).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacoepidemiology, Social and Administrative Pharmacy (PSAP) Research Unit, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
- Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
- Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
- Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
- Institute of Clinical and Evaluative Sciences, ICES uOttawa, Ottawa, ON, Canada.
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Zitieren
APA
Mongkhon, P., Ruengorn, C., Awiphan, R., Phosuya, C., Ruanta, Y., Thavorn, K., Jamjanya, S., Chuamanochan, M., & Nochaiwong, S. (2023). Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1281050
Vancouver
Mongkhon P, Ruengorn C, Awiphan R, Phosuya C, Ruanta Y, Thavorn K, et al. Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1281050
BibTeX
@article{Mongkhon2023,
author = {Mongkhon, Pajaree and Ruengorn, Chidchanok and Awiphan, Ratanaporn and Phosuya, Chabaphai and Ruanta, Yongyuth and Thavorn, Kednapa and Jamjanya, Sirinda and Chuamanochan, Mati and Nochaiwong, Surapon},
title = {Efficacy and safety of metformin for melasma treatment: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1281050}
}
EUVIMED